🔎 Trials Near Me

Pradžia › Dermatomiozitas › Masčusetsas

Dermatomiozitas klinikiniai tyrimai Masčusetsas

5 tyrimai dėl Dermatomiozitas ieško dalyvių vietose Masčusetsas.

Miestai Masčusetsas

Oficialus tyrimo tekstas (anglų kalba)

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

  • Research Site, Boston
Renkami dalyviai3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-24 · NCT06455449

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT03816345

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

  • Boston Children's Hospital - Accepting Young Adults and Juvenile Patients, Boston
Renkami dalyviai2/3 fazė
Amžius nuo 6 iki 75 · Visoms lytims · Atnaujinta 2026-09-17 · NCT06154252

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

  • Brigham and Women's Hospital, Boston
  • CTC - Brigham & Women's Hospital, Boston
  • CTH - Brigham & Women's Hospital, Boston
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-15 · NCT05895786

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

  • Brigham And Womens Hospital, Boston
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-14 · NCT07115745

Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.